Cancer biomarkers serve as crucial compasses in the realm of cancer research, providing pivotal clues into diagnosis, prognosis, and treatment efficacy. These biological indicators encompass a diverse array of molecules—ranging from proteins to genes—found in bodily fluids, tissues, or blood. Their analysis enables the detection of cancer at earlier stages, prognostication of disease trajectory, and customization of treatment plans tailored to individual patients. Recent strides in technology, such as genomic sequencing and liquid biopsies, have significantly augmented the precision and scope of biomarker identification. Moreover, ongoing investigations are dedicated to unearthing novel biomarkers capable of revolutionizing early detection methods and enhancing patient outcomes, thus charting a promising course toward personalized cancer management.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China